Medtronic Inc

MDT-N

NYSE:MDT

111.72
0.68 (0.61%)

Analysis and Opinions about MDT-N

Signal
Opinion
Expert
BUY
BUY
October 17, 2019
Good company. Biggest product is pacemakers. Trades at 19x earnings. Good stock price stability. Trades attractively against peers. Given the multiple, and predictability of earnings, you should look at a 10% return or greater over time.
Medtronic Inc (MDT-N)
October 17, 2019
Good company. Biggest product is pacemakers. Trades at 19x earnings. Good stock price stability. Trades attractively against peers. Given the multiple, and predictability of earnings, you should look at a 10% return or greater over time.
Gordon Reid
President, GoodReid Investment Counsel
Price
$108.740
Owned
No
TOP PICK
TOP PICK
October 2, 2019
They built the first pacemaker and have gone on to make several similar devices. They have gone global. Places like India need these devices for heart disease, for example. The CEO is from Bangladesh and understands this vast market. They are moving from selling the device to improving people's health. If they succeed, they will be hugely profitable. (Analysts’ price target is $116.38)
Medtronic Inc (MDT-N)
October 2, 2019
They built the first pacemaker and have gone on to make several similar devices. They have gone global. Places like India need these devices for heart disease, for example. The CEO is from Bangladesh and understands this vast market. They are moving from selling the device to improving people's health. If they succeed, they will be hugely profitable. (Analysts’ price target is $116.38)
Michael Decter
President & CEO, Lawrence Decter Investment Counsel
Price
$105.940
Owned
Yes
BUY
BUY
September 6, 2019
The stock couldn’t look any better. An absolute buy and hold. It took a long time to break through $100 but they’ve done it. Would be a buyer here.
Medtronic Inc (MDT-N)
September 6, 2019
The stock couldn’t look any better. An absolute buy and hold. It took a long time to break through $100 but they’ve done it. Would be a buyer here.
Elliott Fishman
Director of U.S. and international equity trading, Trading Services Group, Scotia Wealth
Price
$108.690
Owned
No
HOLD
HOLD
May 3, 2019
Don't sell it just to go into a Merck. Add to your diversity instead by buying a basket. Likes Medtronic. Diversified. Into robotic surgery. 8% EPS growth. Relatively inexpensive. Very large, so you don't get the same growth as smaller companies.
Don't sell it just to go into a Merck. Add to your diversity instead by buying a basket. Likes Medtronic. Diversified. Into robotic surgery. 8% EPS growth. Relatively inexpensive. Very large, so you don't get the same growth as smaller companies.
Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$89.580
Owned
Unknown
BUY
BUY
December 3, 2018
Likes it very much. Thought bought Covidien, a medical device maker, a few years back. They're executing very well, such as their diabetes franchise which boosted their guidance recently to 5.5% growth in 2019. Valuation good at 17.5x vs. peers. Many of their products are essential services which is anothe tailwind.
Medtronic Inc (MDT-N)
December 3, 2018
Likes it very much. Thought bought Covidien, a medical device maker, a few years back. They're executing very well, such as their diabetes franchise which boosted their guidance recently to 5.5% growth in 2019. Valuation good at 17.5x vs. peers. Many of their products are essential services which is anothe tailwind.
Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$98.750
Owned
Yes
PAST TOP PICK
PAST TOP PICK
September 18, 2018

(A Top Pick November 13, 2017. Up 24%). He owned this as a diversified play on the medical device market. He sold the stock when it reached $90 and used the proceeds to buy Boston Scientific instead.

Medtronic Inc (MDT-N)
September 18, 2018

(A Top Pick November 13, 2017. Up 24%). He owned this as a diversified play on the medical device market. He sold the stock when it reached $90 and used the proceeds to buy Boston Scientific instead.

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$96.880
Owned
Yes
WEAK BUY
WEAK BUY
May 9, 2018

He likes medical device manufacturers. It seems they are taking market share in a booming market. They are well diversified. The company continues to put up great numbers.

He likes medical device manufacturers. It seems they are taking market share in a booming market. They are well diversified. The company continues to put up great numbers.

Cameron Hurst
Chief Investment Officer, Equium Capital Management
Price
$84.060
Owned
No
BUY
BUY
March 21, 2018

Likes this. One of the most dominant medtech companies, diversified from hips and knees to cardio. Good 15x forward earnings and a stable dividend yield. It's an economy of scale game in medtech, and MDT is well-positioned. Great
balance sheet and growth profile.

Medtronic Inc (MDT-N)
March 21, 2018

Likes this. One of the most dominant medtech companies, diversified from hips and knees to cardio. Good 15x forward earnings and a stable dividend yield. It's an economy of scale game in medtech, and MDT is well-positioned. Great
balance sheet and growth profile.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$80.040
Owned
Unknown
COMMENT
COMMENT
January 31, 2018

A dividend aristocrat, gradually increasing the dividend every year. They are in medical devices. Any increase in surgery, hospital time and heart disease would be an upside for this story. It’s been a relative laggard for the group, but has been a very good performer longer-term, and has rewarded shareholders very well. Sees this as a mutual fund of device companies.

Medtronic Inc (MDT-N)
January 31, 2018

A dividend aristocrat, gradually increasing the dividend every year. They are in medical devices. Any increase in surgery, hospital time and heart disease would be an upside for this story. It’s been a relative laggard for the group, but has been a very good performer longer-term, and has rewarded shareholders very well. Sees this as a mutual fund of device companies.

Darren Sissons
Vice President and Partner, Campbell Lee & Ross
Price
$85.890
Owned
Yes
HOLD
HOLD
January 11, 2018

Medical devices. A good global name. He has been bullish on medical devices for quite some time. He has shifted that down recently because it was getting close to his break points. Earnings were ratcheted down because of hurricane noise because of Puerto Rican noise. IHI-N is the US ETF he would use to take positions in this sector. You want to get through this next quarter. You have good metrics.

Medtronic Inc (MDT-N)
January 11, 2018

Medical devices. A good global name. He has been bullish on medical devices for quite some time. He has shifted that down recently because it was getting close to his break points. Earnings were ratcheted down because of hurricane noise because of Puerto Rican noise. IHI-N is the US ETF he would use to take positions in this sector. You want to get through this next quarter. You have good metrics.

Cameron Hurst
Chief Investment Officer, Equium Capital Management
Price
$85.730
Owned
Unknown
TOP PICK
TOP PICK
November 13, 2017

This does stuff mainly related to cardiovascular, diabetes, spinal implants and a lot of neurology stuff. The stock has been bouncing between $90 and $75. Has 4%-5% earnings growth. Dividend yield of 2.3%. (Analysts’ price target is $90.)

Medtronic Inc (MDT-N)
November 13, 2017

This does stuff mainly related to cardiovascular, diabetes, spinal implants and a lot of neurology stuff. The stock has been bouncing between $90 and $75. Has 4%-5% earnings growth. Dividend yield of 2.3%. (Analysts’ price target is $90.)

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$79.200
Owned
Yes
COMMENT
COMMENT
October 13, 2017

This has certainly had its good days. It’s been quite a good company for many years. He likes the medical technology space.

Medtronic Inc (MDT-N)
October 13, 2017

This has certainly had its good days. It’s been quite a good company for many years. He likes the medical technology space.

Matt Kacur
President, FSA Financial Science and Art
Price
$78.070
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
May 23, 2017

(A Top Pick May 25/16. Up 7%.) He really likes the medical device space. If he were to buy something today, he would probably buy a Stryker (SYK-N). The nice thing about devices is that it is not completely dependent on insurance pays. If you would like the whole sector, you can buy the ETF IHI-N.

(A Top Pick May 25/16. Up 7%.) He really likes the medical device space. If he were to buy something today, he would probably buy a Stryker (SYK-N). The nice thing about devices is that it is not completely dependent on insurance pays. If you would like the whole sector, you can buy the ETF IHI-N.

David Burrows
President & Chief Investment Strategist, Barometer Capital Management
Price
$84.610
Owned
No
WEAK BUY
WEAK BUY
April 24, 2017

They have struggled over the most recent years after being a darling. There is the question of how healthcare will be paid for in the US. Device companies have the hardest headwinds. They are also in a very competitive area. It is not expensive and is a perfectly good way to be in the health care area. Their struggles may mean they have more upside potential if the healthcare sector improves.

Medtronic Inc (MDT-N)
April 24, 2017

They have struggled over the most recent years after being a darling. There is the question of how healthcare will be paid for in the US. Device companies have the hardest headwinds. They are also in a very competitive area. It is not expensive and is a perfectly good way to be in the health care area. Their struggles may mean they have more upside potential if the healthcare sector improves.

Liz Miller
President, Summit Place Financial Advisors
Price
$80.650
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
April 19, 2017

(A Top Pick May 13/16. Up 2%.) The leading medical device company. He owns it because they have a plethora of products right across the range. They had a bit of an earnings hit in the 3rd quarter, and he bought more. He has a $92 target on this.

Medtronic Inc (MDT-N)
April 19, 2017

(A Top Pick May 13/16. Up 2%.) The leading medical device company. He owns it because they have a plethora of products right across the range. They had a bit of an earnings hit in the 3rd quarter, and he bought more. He has a $92 target on this.

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$80.320
Owned
Yes
DON'T BUY
DON'T BUY
April 6, 2017

There has been some major earnings volatility around this one recently. So he has backed off. They have a mid- to high- single digit earnings growth rate, but you are paying twice that. The PE to growth rate is too high. You are paying top dollar for the growth you are getting.

Medtronic Inc (MDT-N)
April 6, 2017

There has been some major earnings volatility around this one recently. So he has backed off. They have a mid- to high- single digit earnings growth rate, but you are paying twice that. The PE to growth rate is too high. You are paying top dollar for the growth you are getting.

Cameron Hurst
Chief Investment Officer, Equium Capital Management
Price
$80.220
Owned
Unknown
COMMENT
COMMENT
February 22, 2017

This has everything you can think of that is tools related, from your head all the way down to your toes; cardiovascular, stent. The dominant player in medical technologies. Trading at 17X next year’s earnings. Had a hiccup last quarter, but all they had to do was show that things were back on track. He likes this.

Medtronic Inc (MDT-N)
February 22, 2017

This has everything you can think of that is tools related, from your head all the way down to your toes; cardiovascular, stent. The dominant player in medical technologies. Trading at 17X next year’s earnings. Had a hiccup last quarter, but all they had to do was show that things were back on track. He likes this.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$79.620
Owned
Yes
PAST TOP PICK
PAST TOP PICK
January 25, 2017

(A Top Pick Oct 11/16. Down 9.87%.) For the most part of 2016, there was a rotation out of Pharma and into medical devices. Great company, well-established and a good yield.

Medtronic Inc (MDT-N)
January 25, 2017

(A Top Pick Oct 11/16. Down 9.87%.) For the most part of 2016, there was a rotation out of Pharma and into medical devices. Great company, well-established and a good yield.

Dean Orrico
President, Middlefield Capital Corp.
Price
$74.490
Owned
Yes
COMMENT
COMMENT
October 17, 2016

He likes healthcare “devices”, because it is the area that is least likely to be attacked by a government. They are somewhat less regulated from a price standpoint. This company has very strong market share in rhythm devices. Earnings for the year should be up about 7% over last year, but should accelerate up to about 11% next year. It has consolidated between $80 and $90 going back to June. Sitting at around the 150 day moving average, so technically is in a good spot. You should see earnings accelerate going forward, which is what he cares about.

Medtronic Inc (MDT-N)
October 17, 2016

He likes healthcare “devices”, because it is the area that is least likely to be attacked by a government. They are somewhat less regulated from a price standpoint. This company has very strong market share in rhythm devices. Earnings for the year should be up about 7% over last year, but should accelerate up to about 11% next year. It has consolidated between $80 and $90 going back to June. Sitting at around the 150 day moving average, so technically is in a good spot. You should see earnings accelerate going forward, which is what he cares about.

David Burrows
President & Chief Investment Strategist, Barometer Capital Management
Price
$82.570
Owned
Unknown
DON'T BUY
DON'T BUY
October 14, 2016

Seasonally, this doesn’t do too well at this time of year. That is pretty common for all the healthcare instrument stocks in general. Technically it is developing a downward trend and recently broke 2 support levels.

Medtronic Inc (MDT-N)
October 14, 2016

Seasonally, this doesn’t do too well at this time of year. That is pretty common for all the healthcare instrument stocks in general. Technically it is developing a downward trend and recently broke 2 support levels.

Don Vialoux
Research Analyst, TimingTheMarket.CA & EquityClock.COM
Price
$82.710
Owned
Unknown
TOP PICK
TOP PICK
October 11, 2016

A medical device business, one of the largest in the world. A very diverse product line. Valuation at about 18X earnings, the high end of the range, but medical devices are trading at a premium to Pharma. He sees single digit revenue growth and double digit earnings growth, and expects some real growth to come out of things like aortic valve replacement. Dividend yield of 2.07%.

Medtronic Inc (MDT-N)
October 11, 2016

A medical device business, one of the largest in the world. A very diverse product line. Valuation at about 18X earnings, the high end of the range, but medical devices are trading at a premium to Pharma. He sees single digit revenue growth and double digit earnings growth, and expects some real growth to come out of things like aortic valve replacement. Dividend yield of 2.07%.

Dean Orrico
President, Middlefield Capital Corp.
Price
$83.200
Owned
Yes
HOLD
HOLD
October 4, 2016

Has a target price of $98, so there is decent upside to it. They are talking about launching a robotic surgery system, so that is something to keep an eye on. It is not at the top of his list, so he wouldn’t be adding to it here.

Medtronic Inc (MDT-N)
October 4, 2016

Has a target price of $98, so there is decent upside to it. They are talking about launching a robotic surgery system, so that is something to keep an eye on. It is not at the top of his list, so he wouldn’t be adding to it here.

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$86.110
Owned
Yes
TOP PICK
TOP PICK
September 23, 2016

In general he has been cautious on Biotechs, but this is a medical devices company. It is very, very solid. In the next 5 years it should be growing revenues at mid-single digits. Earnings at low double digits. Dividend yield of 1.96%.

Medtronic Inc (MDT-N)
September 23, 2016

In general he has been cautious on Biotechs, but this is a medical devices company. It is very, very solid. In the next 5 years it should be growing revenues at mid-single digits. Earnings at low double digits. Dividend yield of 1.96%.

John Stephenson
President & CEO, Stephenson & Company Capital Management
Price
$87.710
Owned
Yes
COMMENT
COMMENT
September 1, 2016

The medical device companies have done a lot better this year, versus pharmaceutical companies. If you are buying shares of a healthcare company right now, he would buy a pharmaceutical name or his Top Pick at the end. (See Top Picks.)

Medtronic Inc (MDT-N)
September 1, 2016

The medical device companies have done a lot better this year, versus pharmaceutical companies. If you are buying shares of a healthcare company right now, he would buy a pharmaceutical name or his Top Pick at the end. (See Top Picks.)

Barry Schwartz
CIO & Portfolio Manager, Baskin Wealth Management
Price
$86.980
Owned
Unknown
TOP PICK
TOP PICK
August 30, 2016

A healthcare company, but not a pharmaceutical company. They are very big in cardiovascular and diabetes. Growing their top line at roughly 5%-10% per annum, and the bottom line closer to 12%-13% for the foreseeable future for the next 4-5 years. They are in the right place at the right time, and are likely to return about $1 billion a year to the shareholders for the next few years. They are committed to increasing their dividends. Dividend yield of 1.98%.

Medtronic Inc (MDT-N)
August 30, 2016

A healthcare company, but not a pharmaceutical company. They are very big in cardiovascular and diabetes. Growing their top line at roughly 5%-10% per annum, and the bottom line closer to 12%-13% for the foreseeable future for the next 4-5 years. They are in the right place at the right time, and are likely to return about $1 billion a year to the shareholders for the next few years. They are committed to increasing their dividends. Dividend yield of 1.98%.

John Stephenson
President & CEO, Stephenson & Company Capital Management
Price
$86.850
Owned
Yes
PAST TOP PICK
PAST TOP PICK
July 13, 2016

(Top Pick May 13/16, Down 9%) They gave positive guidance last earnings report. Healthcare stocks are starting to work over the last two to three weeks.

Medtronic Inc (MDT-N)
July 13, 2016

(Top Pick May 13/16, Down 9%) They gave positive guidance last earnings report. Healthcare stocks are starting to work over the last two to three weeks.

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$88.750
Owned
Yes
HOLD
HOLD
July 7, 2016

Was a darling in the sector. She views it as a steady eddy right now. It is an acceptable hold if you are diversifying your healthcare holdings. She likes the company as a long term hold of 5 years.

Was a darling in the sector. She views it as a steady eddy right now. It is an acceptable hold if you are diversifying your healthcare holdings. She likes the company as a long term hold of 5 years.

Liz Miller
President, Summit Place Financial Advisors
Price
$87.490
Owned
Unknown
HOLD
HOLD
June 22, 2016

Acquired Covidien about a year or so ago. A very synergistic acquisition. Has had a great run. A name he would absolutely continue to hold onto. Great balance sheet. Growing in their businesses. His preferred choice in medical devices.

Medtronic Inc (MDT-N)
June 22, 2016

Acquired Covidien about a year or so ago. A very synergistic acquisition. Has had a great run. A name he would absolutely continue to hold onto. Great balance sheet. Growing in their businesses. His preferred choice in medical devices.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$84.260
Owned
Yes
PAST TOP PICK
PAST TOP PICK
June 21, 2016

(A Top Pick Sept 18/15. Up 22.15%.) Their merger with Covidien has worked out well, and they successfully moved their headquarters to Ireland. There continues to be hefty chunks of cash flow that can be used for tuck in acquisitions or further dividend increases down the road.

Medtronic Inc (MDT-N)
June 21, 2016

(A Top Pick Sept 18/15. Up 22.15%.) Their merger with Covidien has worked out well, and they successfully moved their headquarters to Ireland. There continues to be hefty chunks of cash flow that can be used for tuck in acquisitions or further dividend increases down the road.

Mohsin Bashir
VP Investments, Stone Asset Management
Price
$84.590
Owned
Yes
COMMENT
COMMENT
June 14, 2016

He likes healthcare, and specifically medical devices. This company is big on implants, both for heart and minimally invasive, as well spinal implants. With an aging population, a lot of replacement parts are required, and this company is doing a great job. 1.8% dividend yield. He likes the stock.

Medtronic Inc (MDT-N)
June 14, 2016

He likes healthcare, and specifically medical devices. This company is big on implants, both for heart and minimally invasive, as well spinal implants. With an aging population, a lot of replacement parts are required, and this company is doing a great job. 1.8% dividend yield. He likes the stock.

David Burrows
President & Chief Investment Strategist, Barometer Capital Management
Price
$85.490
Owned
Yes
Showing 1 to 30 of 76 entries